ALT
Altimmune Inc
2.70$
-2.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5,659.4% | -44,683.8% | -327,140.0% | -362,160.0% | -542,360.0% | -365,300.0% | -336,800.0% | -387,000.0% | -237,940.0% | -74,800.0% | – | – | -246,800.0% | |
| -152.5% | 5,108.1% | 2,140.0% | 1,220.0% | 740.0% | 660.0% | 580.0% | 600.0% | 540.0% | 100.0% | – | – | 319.4% | |
| 748.6% | 6,673.0% | 73,000.0% | 86,220.0% | 61,560.0% | 67,080.0% | 80,300.0% | 71,320.0% | 71,080.0% | 19,003.8% | – | – | 47,293.5% | |
| 748.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -544.8% | 2,218.9% | 105,100.0% | 63,120.0% | -168,220.0% | 49,280.0% | 1,460.0% | -9,440.0% | 70,660.0% | 13,915.4% | – | – | 2,887.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 200.0% | 0.0% | 3.8% | – | – | 174.2% | |
| 1,216.0% | -21,510.8% | -790,420.0% | -73,920.0% | 23,980.0% | 272,640.0% | -102,020.0% | 2,022,140.0% | -2,986,420.0% | -304,453.8% | – | – | -1,463,264.5% | |
| -0.6% | -100.0% | -12,000.0% | -4,880.0% | 22,880.0% | – | 3,400.0% | – | 2,420.0% | – | – | – | – | |
| – | – | – | – | 0.0% | – | – | – | 8,080.0% | 76,923.1% | – | – | – | |
| 162.4% | 196,632.4% | -5,220.0% | -920.0% | 5,320.0% | 201,700.0% | 682,380.0% | 1,044,880.0% | 786,980.0% | 312,038.5% | – | – | 1,322,654.8% | |
| -4,280.9% | 130,437.8% | -1,122,780.0% | -437,000.0% | -513,060.0% | 109,040.0% | 243,560.0% | 2,680,020.0% | -2,437,380.0% | -67,215.4% | – | – | -387,409.7% | |
| -5,659.4% | -44,683.8% | -327,140.0% | -362,160.0% | -542,360.0% | -365,300.0% | -336,800.0% | -387,200.0% | -237,940.0% | -74,803.8% | – | – | -246,974.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.